<a id='910c2ee9-e028-4771-a3fd-e6edfd9f250e'></a>

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
...
<table id="0-1">
<tr><td id="0-2"></td><td id="0-3"></td><td id="0-4">Page</td></tr>
<tr><td id="0-5" colspan="2">Consolidated Financial Statements</td><td id="0-6"></td></tr>
<tr><td id="0-7" colspan="2">Consolidated Statements of Earnings</td><td id="0-8">55</td></tr>
<tr><td id="0-9" colspan="2">Consolidated Statements of Comprehensive Income</td><td id="0-a">56</td></tr>
<tr><td id="0-b" colspan="2">Consolidated Balance Sheets</td><td id="0-c">57</td></tr>
<tr><td id="0-d" colspan="2">Consolidated Statements of Equity</td><td id="0-e">58</td></tr>
<tr><td id="0-f" colspan="2">Consolidated Statements of Cash Flows</td><td id="0-g">59</td></tr>
<tr><td id="0-h" colspan="2">Notes to Consolidated Financial Statements</td><td id="0-i"></td></tr>
<tr><td id="0-j">Note 1</td><td id="0-k">Background</td><td id="0-l">60</td></tr>
<tr><td id="0-m">Note 2</td><td id="0-n">Summary of Significant Accounting Policies</td><td id="0-o">60</td></tr>
<tr><td id="0-p">Note 3</td><td id="0-q">Supplemental Financial Information</td><td id="0-r">66</td></tr>
<tr><td id="0-s">Note 4</td><td id="0-t">Earnings Per Share</td><td id="0-u">66</td></tr>
<tr><td id="0-v">Note 5</td><td id="0-w">Licensing, Acquisitions and Other Arrangements</td><td id="0-x">67</td></tr>
<tr><td id="0-y">Note 6</td><td id="0-z">Collaborations</td><td id="0-A">73</td></tr>
<tr><td id="0-B">Note 7</td><td id="0-C">Goodwill and Intangible Assets</td><td id="0-D">74</td></tr>
<tr><td id="0-E">Note 8</td><td id="0-F">Restructuring Plans</td><td id="0-G">76</td></tr>
<tr><td id="0-H">Note 9</td><td id="0-I">Leases</td><td id="0-J">77</td></tr>
<tr><td id="0-K">Note 10</td><td id="0-L">Debt, Credit Facilities and Commitments and Contingencies</td><td id="0-M">78</td></tr>
<tr><td id="0-N">Note 11</td><td id="0-O">Financial Instruments and Fair Value Measures</td><td id="0-P">81</td></tr>
<tr><td id="0-Q">Note 12</td><td id="0-R">Post-Employment Benefits</td><td id="0-S">87</td></tr>
<tr><td id="0-T">Note 13</td><td id="0-U">Equity</td><td id="0-V">92</td></tr>
<tr><td id="0-W">Note 14</td><td id="0-X">Income Taxes</td><td id="0-Y">96</td></tr>
<tr><td id="0-Z">Note 15</td><td id="0-10">Legal Proceedings and Contingencies</td><td id="0-11">99</td></tr>
<tr><td id="0-12">Note 16</td><td id="0-13">Segment and Geographic Area Information</td><td id="0-14">102</td></tr>
<tr><td id="0-15">Note 17</td><td id="0-16">Fourth Quarter Financial Results (unaudited)</td><td id="0-17">104</td></tr>
<tr><td id="0-18" colspan="2">Report of Independent Registered Public Accounting Firm (PCAOB ID: 42)</td><td id="0-19">105</td></tr>
</table>

<a id='12388799-9f22-43d8-adb0-fa3d355914a9'></a>

54

<a id='a2847e5e-066d-4063-92d2-339407e0b7f6'></a>

abbvie | 2024 Form 10-K

<!-- PAGE BREAK -->

<a id='1fada543-7645-4356-80c5-8111a4a8cd16'></a>

AbbVie Inc. and Subsidiaries
Consolidated Statements of Earnings
<table id="1-1">
<tr><td id="1-2">years ended December 31 (in millions, except per share data)</td><td id="1-3">2024</td><td id="1-4">2023</td><td id="1-5">2022</td></tr>
<tr><td id="1-6">Net revenues</td><td id="1-7">$56,334</td><td id="1-8">$54,318</td><td id="1-9">$58,054</td></tr>
<tr><td id="1-a">Cost of products sold</td><td id="1-b">16,904</td><td id="1-c">20,415</td><td id="1-d">17,414</td></tr>
<tr><td id="1-e">Selling, general and administrative</td><td id="1-f">14,752</td><td id="1-g">12,872</td><td id="1-h">15,260</td></tr>
<tr><td id="1-i">Research and development</td><td id="1-j">12,791</td><td id="1-k">7,675</td><td id="1-l">6,510</td></tr>
<tr><td id="1-m">Acquired IPR&amp;D and milestones</td><td id="1-n">2,757</td><td id="1-o">778</td><td id="1-p">697</td></tr>
<tr><td id="1-q">Other operating expense (income), net</td><td id="1-r">(7)</td><td id="1-s">(179)</td><td id="1-t">56</td></tr>
<tr><td id="1-u">Total operating costs and expenses</td><td id="1-v">47,197</td><td id="1-w">41,561</td><td id="1-x">39,937</td></tr>
<tr><td id="1-y">Operating earnings</td><td id="1-z">9,137</td><td id="1-A">12,757</td><td id="1-B">18,117</td></tr>
<tr><td id="1-C">Interest expense, net</td><td id="1-D">2,160</td><td id="1-E">1,684</td><td id="1-F">2,044</td></tr>
<tr><td id="1-G">Net foreign exchange loss</td><td id="1-H">21</td><td id="1-I">146</td><td id="1-J">148</td></tr>
<tr><td id="1-K">Other expense, net</td><td id="1-L">3,240</td><td id="1-M">4,677</td><td id="1-N">2,448</td></tr>
<tr><td id="1-O">Earnings before income tax expense</td><td id="1-P">3,716</td><td id="1-Q">6,250</td><td id="1-R">13,477</td></tr>
<tr><td id="1-S">Income tax expense (benefit)</td><td id="1-T">(570)</td><td id="1-U">1,377</td><td id="1-V">1,632</td></tr>
<tr><td id="1-W">Net earnings</td><td id="1-X">4,286</td><td id="1-Y">4,873</td><td id="1-Z">11,845</td></tr>
<tr><td id="1-10">Net earnings attributable to noncontrolling interest</td><td id="1-11">8</td><td id="1-12">10</td><td id="1-13">9</td></tr>
<tr><td id="1-14">Net earnings attributable to AbbVie Inc.</td><td id="1-15">$ 4,278</td><td id="1-16">$ 4,863</td><td id="1-17">$11,836</td></tr>
<tr><td id="1-18" colspan="4">Per share data</td></tr>
<tr><td id="1-19">Basic earnings per share attributable to AbbVie Inc.</td><td id="1-1a">$ 2.40</td><td id="1-1b">$ 2.73</td><td id="1-1c">$ 6.65</td></tr>
<tr><td id="1-1d">Diluted earnings per share attributable to AbbVie Inc.</td><td id="1-1e">$ 2.39</td><td id="1-1f">$ 2.72</td><td id="1-1g">$ 6.63</td></tr>
<tr><td id="1-1h">Weighted-average basic shares outstanding</td><td id="1-1i">1,769</td><td id="1-1j">1,768</td><td id="1-1k">1,771</td></tr>
<tr><td id="1-1l">Weighted-average diluted shares outstanding</td><td id="1-1m">1,773</td><td id="1-1n">1,773</td><td id="1-1o">1,778</td></tr>
</table>

<a id='c6b0dc0b-eb17-46bc-a0a6-3f0b305f3ac1'></a>

The accompanying notes are an integral part of these consolidated financial statements.

<a id='4498885f-2c04-4039-af87-6f8f61fbc8a6'></a>

2024 Form 10-K | abbvie 55

<!-- PAGE BREAK -->

<a id='9e0e9d73-c28c-43dc-98bd-bfe986e74de9'></a>

AbbVie Inc. and Subsidiaries
Consolidated Statements of Comprehensive Income
<table id="2-1">
<tr><td id="2-2">years ended December 31 (in millions)</td><td id="2-3">2024</td><td id="2-4">2023</td><td id="2-5">2022</td></tr>
<tr><td id="2-6">Net earnings</td><td id="2-7">$ 4,286</td><td id="2-8">$4,873</td><td id="2-9">$11,845</td></tr>
<tr><td id="2-a">Foreign currency translation adjustments, net of tax expense (benefit) of $(39) in 2024, $15 in 2023 and $(10) in 2022</td><td id="2-b">(1,008)</td><td id="2-c">407</td><td id="2-d">(943)</td></tr>
<tr><td id="2-e">Net investment hedging activities, net of tax expense (benefit) of $133 in 2024, $(109) in 2023 and $152 in 2022</td><td id="2-f">484</td><td id="2-g">(399)</td><td id="2-h">555</td></tr>
<tr><td id="2-i">Pension and post-employment benefits, net of tax expense (benefit) of $206 in 2024, $(6) in 2023 and $272 in 2022</td><td id="2-j">824</td><td id="2-k">(30)</td><td id="2-l">1,088</td></tr>
<tr><td id="2-m">Cash flow hedging activities, net of tax expense (benefit) of $16 in 2024, $(19) in 2023 and $5 in 2022</td><td id="2-n">80</td><td id="2-o">(84)</td><td id="2-p">—</td></tr>
<tr><td id="2-q">Other comprehensive income (loss)</td><td id="2-r">$ 380</td><td id="2-s">$ (106)</td><td id="2-t">$ 700</td></tr>
<tr><td id="2-u">Comprehensive income</td><td id="2-v">4,666</td><td id="2-w">4,767</td><td id="2-x">12,545</td></tr>
<tr><td id="2-y">Comprehensive income attributable to noncontrolling interest</td><td id="2-z">8</td><td id="2-A">10</td><td id="2-B">9</td></tr>
<tr><td id="2-C">Comprehensive income attributable to AbbVie Inc.</td><td id="2-D">$ 4,658</td><td id="2-E">$4,757</td><td id="2-F">$12,536</td></tr>
</table>

<a id='c93c1122-3a87-4103-9f25-4eb9b6d6d1b2'></a>

The accompanying notes are an integral part of these consolidated financial statements.

<a id='a481d941-8d64-4543-b44f-cbf50cc14717'></a>

56

<a id='40bff26f-509a-4a0b-867e-6059535e119c'></a>

abbvie | 2024 Form 10-K

<!-- PAGE BREAK -->

<a id='9bd7a010-fec0-4da1-9be2-57049b848ff4'></a>

AbbVie Inc. and Subsidiaries
Consolidated Balance Sheets

<a id='d2f3ff36-e566-4180-9774-98ccbec536fb'></a>

<table id="3-1">
<tr><td id="3-2">as of December 31 (in millions, except share data)</td><td id="3-3">2024</td><td id="3-4">2023</td></tr>
<tr><td id="3-5" colspan="3">Assets</td></tr>
<tr><td id="3-6" colspan="3">Current assets</td></tr>
<tr><td id="3-7">Cash and equivalents</td><td id="3-8">$ 5,524</td><td id="3-9">$ 12,814</td></tr>
<tr><td id="3-a">Short-term investments</td><td id="3-b">31</td><td id="3-c">2</td></tr>
<tr><td id="3-d">Accounts receivable, net</td><td id="3-e">10,919</td><td id="3-f">11,155</td></tr>
<tr><td id="3-g">Inventories</td><td id="3-h">4,181</td><td id="3-i">4,099</td></tr>
<tr><td id="3-j">Prepaid expenses and other</td><td id="3-k">4,927</td><td id="3-l">4,932</td></tr>
<tr><td id="3-m">Total current assets</td><td id="3-n">25,582</td><td id="3-o">33,002</td></tr>
<tr><td id="3-p">Investments</td><td id="3-q">279</td><td id="3-r">304</td></tr>
<tr><td id="3-s">Property and equipment, net</td><td id="3-t">5,134</td><td id="3-u">4,989</td></tr>
<tr><td id="3-v">Intangible assets, net</td><td id="3-w">60,068</td><td id="3-x">55,610</td></tr>
<tr><td id="3-y">Goodwill</td><td id="3-z">34,956</td><td id="3-A">32,293</td></tr>
<tr><td id="3-B">Other assets</td><td id="3-C">9,142</td><td id="3-D">8,513</td></tr>
<tr><td id="3-E">Total assets</td><td id="3-F">$135,161</td><td id="3-G">$134,711</td></tr>
<tr><td id="3-H" colspan="3">Liabilities and Equity</td></tr>
<tr><td id="3-I" colspan="3">Current liabilities</td></tr>
<tr><td id="3-J">Current portion of long-term debt and finance lease obligations</td><td id="3-K">$ 6,804</td><td id="3-L">$ 7,191</td></tr>
<tr><td id="3-M">Accounts payable and accrued liabilities</td><td id="3-N">31,945</td><td id="3-O">30,650</td></tr>
<tr><td id="3-P">Total current liabilities</td><td id="3-Q">38,749</td><td id="3-R">37,841</td></tr>
<tr><td id="3-S">Long-term debt and finance lease obligations</td><td id="3-T">60,340</td><td id="3-U">52,194</td></tr>
<tr><td id="3-V">Deferred income taxes</td><td id="3-W">2,579</td><td id="3-X">1,952</td></tr>
<tr><td id="3-Y">Other long-term liabilities</td><td id="3-Z">30,129</td><td id="3-10">32,327</td></tr>
</table>

<a id='20c5fabf-3048-4751-a545-b83306bc3da7'></a>

<table id="3-11">
<tr><td id="3-12">Stockholders&#x27; equity</td><td id="3-13"></td><td id="3-14"></td></tr>
<tr><td id="3-15">Common stock, $0.01 par value, 4,000,000,000 shares authorized, 1,831,594,494 shares issued as of December 31, 2024 and 1,823,046,087 as of December 31, 2023</td><td id="3-16">18</td><td id="3-17">18</td></tr>
<tr><td id="3-18">Common stock held in treasury, at cost, 66,337,508 shares as of December 31, 2024 and 57,105,354 as of December 31, 2023</td><td id="3-19">(8,201)</td><td id="3-1a">(6,533)</td></tr>
<tr><td id="3-1b">Additional paid-in capital</td><td id="3-1c">21,333</td><td id="3-1d">20,180</td></tr>
<tr><td id="3-1e">Accumulated deficit</td><td id="3-1f">(7,900)</td><td id="3-1g">(1,000)</td></tr>
<tr><td id="3-1h">Accumulated other comprehensive loss</td><td id="3-1i">(1,925)</td><td id="3-1j">(2,305)</td></tr>
<tr><td id="3-1k">Total stockholders&#x27; equity</td><td id="3-1l">3,325</td><td id="3-1m">10,360</td></tr>
<tr><td id="3-1n">Noncontrolling interest</td><td id="3-1o">39</td><td id="3-1p">37</td></tr>
<tr><td id="3-1q">Total equity</td><td id="3-1r">3,364</td><td id="3-1s">10,397</td></tr>
<tr><td id="3-1t">Total liabilities and equity</td><td id="3-1u">$135,161</td><td id="3-1v">$134,711</td></tr>
</table>

<a id='688ab90b-469d-4ac2-8df3-635f6ad8a773'></a>

The accompanying notes are an integral part of these consolidated financial statements.

<a id='a17dc4e1-7a2e-43c0-9fa4-02f816acf8e4'></a>

2024 Form 10-K | abbvie 57

<a id='e51917f8-c5f4-4ecd-818e-93333283371a'></a>

Commitments and contingencies

<!-- PAGE BREAK -->

<a id='e10dba2f-fa88-40e7-8dd4-581a80f6e616'></a>

AbbVie Inc. and Subsidiaries
Consolidated Statements of Equity

<a id='73b9ab43-e88a-4044-847b-1058373524af'></a>

<table id="4-1">
<tr><td id="4-2">years ended December 31 (in millions)</td><td id="4-3">Common shares outstanding</td><td id="4-4">Common stock</td><td id="4-5">Treasury stock</td><td id="4-6">Additional paid-in capital</td><td id="4-7">Retained earnings (accumulated deficit)</td><td id="4-8">Accumulated other comprehensive loss</td><td id="4-9">Noncontrolling interest</td><td id="4-a">Total</td></tr>
<tr><td id="4-b">Balance at December 31, 2021</td><td id="4-c">1,768</td><td id="4-d">$18</td><td id="4-e">$(3,143)</td><td id="4-f">$18,305</td><td id="4-g">$ 3,127</td><td id="4-h">$(2,899)</td><td id="4-i">$28</td><td id="4-j">$ 15,436</td></tr>
<tr><td id="4-k">Net earnings attributable to AbbVie Inc.</td><td id="4-l">—</td><td id="4-m">—</td><td id="4-n">—</td><td id="4-o">—</td><td id="4-p">11,836</td><td id="4-q">—</td><td id="4-r">—</td><td id="4-s">11,836</td></tr>
<tr><td id="4-t">Other comprehensive income, net of tax</td><td id="4-u">—</td><td id="4-v">—</td><td id="4-w">—</td><td id="4-x">—</td><td id="4-y">—</td><td id="4-z">700</td><td id="4-A">—</td><td id="4-B">700</td></tr>
<tr><td id="4-C">Dividends declared</td><td id="4-D">—</td><td id="4-E">—</td><td id="4-F">—</td><td id="4-G">—</td><td id="4-H">(10,179)</td><td id="4-I">—</td><td id="4-J">—</td><td id="4-K">(10,179)</td></tr>
<tr><td id="4-L">Purchases of treasury stock</td><td id="4-M">(10)</td><td id="4-N">—</td><td id="4-O">(1,487)</td><td id="4-P">—</td><td id="4-Q">—</td><td id="4-R">—</td><td id="4-S">—</td><td id="4-T">(1,487)</td></tr>
<tr><td id="4-U">Stock-based compensation plans and other</td><td id="4-V">11</td><td id="4-W">—</td><td id="4-X">36</td><td id="4-Y">940</td><td id="4-Z">—</td><td id="4-10">—</td><td id="4-11">—</td><td id="4-12">976</td></tr>
<tr><td id="4-13">Change in noncontrolling interest</td><td id="4-14">—</td><td id="4-15">—</td><td id="4-16">—</td><td id="4-17">—</td><td id="4-18">—</td><td id="4-19">—</td><td id="4-1a">5</td><td id="4-1b">5</td></tr>
<tr><td id="4-1c">Balance at December 31, 2022</td><td id="4-1d">1,769</td><td id="4-1e">18</td><td id="4-1f">(4,594)</td><td id="4-1g">19,245</td><td id="4-1h">4,784</td><td id="4-1i">(2,199)</td><td id="4-1j">33</td><td id="4-1k">17,287</td></tr>
<tr><td id="4-1l">Net earnings attributable to AbbVie Inc.</td><td id="4-1m">—</td><td id="4-1n">—</td><td id="4-1o">—</td><td id="4-1p">—</td><td id="4-1q">4,863</td><td id="4-1r">—</td><td id="4-1s">—</td><td id="4-1t">4,863</td></tr>
<tr><td id="4-1u">Other comprehensive loss, net of tax</td><td id="4-1v">—</td><td id="4-1w">—</td><td id="4-1x">—</td><td id="4-1y">—</td><td id="4-1z">–</td><td id="4-1A">(106)</td><td id="4-1B">–</td><td id="4-1C">(106)</td></tr>
<tr><td id="4-1D">Dividends declared</td><td id="4-1E">—</td><td id="4-1F">—</td><td id="4-1G">—</td><td id="4-1H">—</td><td id="4-1I">(10,647)</td><td id="4-1J">–</td><td id="4-1K">–</td><td id="4-1L">(10,647)</td></tr>
<tr><td id="4-1M">Purchases of treasury stock</td><td id="4-1N">(12)</td><td id="4-1O">—</td><td id="4-1P">(1,978)</td><td id="4-1Q">—</td><td id="4-1R">–</td><td id="4-1S">–</td><td id="4-1T">–</td><td id="4-1U">(1,978)</td></tr>
<tr><td id="4-1V">Stock-based compensation plans and other</td><td id="4-1W">9</td><td id="4-1X">—</td><td id="4-1Y">39</td><td id="4-1Z">935</td><td id="4-20">–</td><td id="4-21">–</td><td id="4-22">–</td><td id="4-23">974</td></tr>
<tr><td id="4-24">Change in noncontrolling interest</td><td id="4-25">—</td><td id="4-26">—</td><td id="4-27">—</td><td id="4-28">—</td><td id="4-29">–</td><td id="4-2a">–</td><td id="4-2b">4</td><td id="4-2c">4</td></tr>
<tr><td id="4-2d">Balance at December 31, 2023</td><td id="4-2e">1,766</td><td id="4-2f">18</td><td id="4-2g">(6,533)</td><td id="4-2h">20,180</td><td id="4-2i">(1,000)</td><td id="4-2j">(2,305)</td><td id="4-2k">37</td><td id="4-2l">10,397</td></tr>
<tr><td id="4-2m">Net earnings attributable to AbbVie Inc.</td><td id="4-2n">–</td><td id="4-2o">–</td><td id="4-2p">–</td><td id="4-2q">–</td><td id="4-2r">4,278</td><td id="4-2s">—</td><td id="4-2t">—</td><td id="4-2u">4,278</td></tr>
<tr><td id="4-2v">Other comprehensive income, net of tax</td><td id="4-2w">–</td><td id="4-2x">–</td><td id="4-2y">–</td><td id="4-2z">–</td><td id="4-2A">—</td><td id="4-2B">380</td><td id="4-2C">—</td><td id="4-2D">380</td></tr>
<tr><td id="4-2E">Dividends declared</td><td id="4-2F">–</td><td id="4-2G">–</td><td id="4-2H">–</td><td id="4-2I">–</td><td id="4-2J">(11,178)</td><td id="4-2K">—</td><td id="4-2L">—</td><td id="4-2M">(11,178)</td></tr>
<tr><td id="4-2N">Purchases of treasury stock</td><td id="4-2O">(9)</td><td id="4-2P">–</td><td id="4-2Q">(1,703)</td><td id="4-2R">–</td><td id="4-2S">—</td><td id="4-2T">—</td><td id="4-2U">—</td><td id="4-2V">(1,703)</td></tr>
<tr><td id="4-2W">Stock-based compensation plans and other</td><td id="4-2X">8</td><td id="4-2Y">—</td><td id="4-2Z">35</td><td id="4-30">1,153</td><td id="4-31">—</td><td id="4-32">—</td><td id="4-33">—</td><td id="4-34">1,188</td></tr>
<tr><td id="4-35">Change in noncontrolling interest</td><td id="4-36">—</td><td id="4-37">—</td><td id="4-38">—</td><td id="4-39">—</td><td id="4-3a">—</td><td id="4-3b">—</td><td id="4-3c">2</td><td id="4-3d">2</td></tr>
<tr><td id="4-3e">Balance at December 31, 2024</td><td id="4-3f">1,765</td><td id="4-3g">$18</td><td id="4-3h">$(8,201)</td><td id="4-3i">$21,333</td><td id="4-3j">$ (7,900)</td><td id="4-3k">$(1,925)</td><td id="4-3l">$39</td><td id="4-3m">$ 3,364</td></tr>
</table>

<a id='ec871e70-8008-4574-9cbc-1bc436955c02'></a>

The accompanying notes are an integral part of these consolidated financial statements.

<a id='cbcc74b9-4eec-4b08-9e50-89eeacc093ab'></a>

58

<a id='d3cd8a65-9c78-4cf0-b914-1395bed8b29a'></a>

abbvie 2024 Form 10-K

<!-- PAGE BREAK -->

<a id='8e568e57-8036-423c-88b6-a8138f58d884'></a>

AbbVie Inc. and Subsidiaries
Consolidated Statements of Cash Flows

<table id="5-1">
<tr><td id="5-2">years ended December 31 (in millions) (brackets denote cash outflows)</td><td id="5-3">2024</td><td id="5-4">2023</td><td id="5-5">2022</td></tr>
<tr><td id="5-6" colspan="4">Cash flows from operating activities</td></tr>
<tr><td id="5-7">Net earnings</td><td id="5-8">$ 4,286</td><td id="5-9">$ 4,873</td><td id="5-a">$ 11,845</td></tr>
<tr><td id="5-b">Adjustments to reconcile net earnings to net cash from operating activities:</td><td id="5-c"></td><td id="5-d"></td><td id="5-e"></td></tr>
<tr><td id="5-f">Depreciation</td><td id="5-g">764</td><td id="5-h">752</td><td id="5-i">778</td></tr>
<tr><td id="5-j">Amortization of intangible assets</td><td id="5-k">7,622</td><td id="5-l">7,946</td><td id="5-m">7,689</td></tr>
<tr><td id="5-n">Deferred income taxes</td><td id="5-o">(1,449)</td><td id="5-p">(2,889)</td><td id="5-q">(1,931)</td></tr>
<tr><td id="5-r">Change in fair value of contingent consideration liabilities</td><td id="5-s">3,771</td><td id="5-t">5,128</td><td id="5-u">2,761</td></tr>
<tr><td id="5-v">Payments of contingent consideration liabilities</td><td id="5-w">(1,995)</td><td id="5-x">(870)</td><td id="5-y">(164)</td></tr>
<tr><td id="5-z">Stock-based compensation</td><td id="5-A">911</td><td id="5-B">747</td><td id="5-C">671</td></tr>
<tr><td id="5-D">Acquired IPR&amp;D and milestones</td><td id="5-E">2,757</td><td id="5-F">778</td><td id="5-G">697</td></tr>
<tr><td id="5-H">Gain on divestitures</td><td id="5-I">—</td><td id="5-J">—</td><td id="5-K">(172)</td></tr>
<tr><td id="5-L">Non-cash litigation reserve adjustments, net of cash payments</td><td id="5-M">508</td><td id="5-N">(443)</td><td id="5-O">2,243</td></tr>
<tr><td id="5-P">Impairment of intangible assets</td><td id="5-Q">4,476</td><td id="5-R">4,229</td><td id="5-S">770</td></tr>
<tr><td id="5-T">Other, net</td><td id="5-U">(63)</td><td id="5-V">(225)</td><td id="5-W">(150)</td></tr>
<tr><td id="5-X">Changes in operating assets and liabilities, net of acquisitions:</td><td id="5-Y"></td><td id="5-Z"></td><td id="5-10"></td></tr>
<tr><td id="5-11">Accounts receivable</td><td id="5-12">207</td><td id="5-13">66</td><td id="5-14">(1,455)</td></tr>
<tr><td id="5-15">Inventories</td><td id="5-16">(319)</td><td id="5-17">(417)</td><td id="5-18">(686)</td></tr>
<tr><td id="5-19">Prepaid expenses and other assets</td><td id="5-1a">361</td><td id="5-1b">(188)</td><td id="5-1c">(264)</td></tr>
<tr><td id="5-1d">Accounts payable and other liabilities</td><td id="5-1e">177</td><td id="5-1f">3,840</td><td id="5-1g">1,769</td></tr>
<tr><td id="5-1h">Income tax assets and liabilities, net</td><td id="5-1i">(3,208)</td><td id="5-1j">(488)</td><td id="5-1k">542</td></tr>
<tr><td id="5-1l">Cash flows from operating activities</td><td id="5-1m">18,806</td><td id="5-1n">22,839</td><td id="5-1o">24,943</td></tr>
<tr><td id="5-1p" colspan="4">Cash flows from investing activities</td></tr>
<tr><td id="5-1q">Acquisition of businesses, net of cash acquired</td><td id="5-1r">(17,493)</td><td id="5-1s">—</td><td id="5-1t">(255)</td></tr>
<tr><td id="5-1u">Other acquisitions and investments</td><td id="5-1v">(3,024)</td><td id="5-1w">(1,223)</td><td id="5-1x">(539)</td></tr>
<tr><td id="5-1y">Acquisitions of property and equipment</td><td id="5-1z">(974)</td><td id="5-1A">(777)</td><td id="5-1B">(695)</td></tr>
<tr><td id="5-1C">Purchases of investment securities</td><td id="5-1D">(73)</td><td id="5-1E">(77)</td><td id="5-1F">(1,438)</td></tr>
<tr><td id="5-1G">Sales and maturities of investment securities</td><td id="5-1H">555</td><td id="5-1I">55</td><td id="5-1J">1,530</td></tr>
<tr><td id="5-1K">Other, net</td><td id="5-1L">189</td><td id="5-1M">13</td><td id="5-1N">774</td></tr>
<tr><td id="5-1O">Cash flows from investing activities</td><td id="5-1P">(20,820)</td><td id="5-1Q">(2,009)</td><td id="5-1R">(623)</td></tr>
<tr><td id="5-1S" colspan="4">Cash flows from financing activities</td></tr>
<tr><td id="5-1T">Proceeds from issuance of other short-term borrowings</td><td id="5-1U">5,008</td><td id="5-1V">–</td><td id="5-1W">–</td></tr>
<tr><td id="5-1X">Repayments of other short-term borrowings</td><td id="5-1Y">(5,008)</td><td id="5-1Z">–</td><td id="5-20">–</td></tr>
<tr><td id="5-21">Proceeds from issuance of long-term debt</td><td id="5-22">16,963</td><td id="5-23">–</td><td id="5-24">2,000</td></tr>
<tr><td id="5-25">Repayments of long-term debt and finance lease obligations</td><td id="5-26">(9,613)</td><td id="5-27">(4,149)</td><td id="5-28">(14,433)</td></tr>
<tr><td id="5-29">Debt issuance costs</td><td id="5-2a">(99)</td><td id="5-2b">(38)</td><td id="5-2c">–</td></tr>
<tr><td id="5-2d">Dividends paid</td><td id="5-2e">(11,025)</td><td id="5-2f">(10,539)</td><td id="5-2g">(10,043)</td></tr>
<tr><td id="5-2h">Purchases of treasury stock</td><td id="5-2i">(1,708)</td><td id="5-2j">(1,972)</td><td id="5-2k">(1,487)</td></tr>
<tr><td id="5-2l">Proceeds from the exercise of stock options</td><td id="5-2m">214</td><td id="5-2n">180</td><td id="5-2o">262</td></tr>
<tr><td id="5-2p">Payments of contingent consideration liabilities</td><td id="5-2q">–</td><td id="5-2r">(752)</td><td id="5-2s">(1,132)</td></tr>
<tr><td id="5-2t">Other, net</td><td id="5-2u">57</td><td id="5-2v">48</td><td id="5-2w">30</td></tr>
<tr><td id="5-2x">Cash flows from financing activities</td><td id="5-2y">(5,211)</td><td id="5-2z">(17,222)</td><td id="5-2A">(24,803)</td></tr>
<tr><td id="5-2B">Effect of exchange rate changes on cash and equivalents</td><td id="5-2C">(65)</td><td id="5-2D">5</td><td id="5-2E">(62)</td></tr>
<tr><td id="5-2F">Net change in cash and equivalents</td><td id="5-2G">(7,290)</td><td id="5-2H">3,613</td><td id="5-2I">(545)</td></tr>
<tr><td id="5-2J">Cash and equivalents, beginning of year</td><td id="5-2K">12,814</td><td id="5-2L">9,201</td><td id="5-2M">9,746</td></tr>
<tr><td id="5-2N">Cash and equivalents, end of year</td><td id="5-2O">$ 5,524</td><td id="5-2P">$ 12,814</td><td id="5-2Q">$ 9,201</td></tr>
<tr><td id="5-2R" colspan="4">Other supplemental information</td></tr>
<tr><td id="5-2S">Interest paid, net of portion capitalized</td><td id="5-2T">$ 2,811</td><td id="5-2U">$ 2,469</td><td id="5-2V">$ 2,546</td></tr>
<tr><td id="5-2W">Income taxes paid</td><td id="5-2X">4,064</td><td id="5-2Y">4,702</td><td id="5-2Z">2,988</td></tr>
</table>

<a id='3277b9bc-4dd4-42c7-81e7-7a7c30435e1b'></a>

The accompanying notes are an integral part of these consolidated financial statements.

<a id='39f998da-960b-4720-91b7-5fc8d50c7929'></a>

2024 Form 10-K | abbvie 59

<!-- PAGE BREAK -->

<a id='b8adb61d-4d3b-4400-a927-fb68fa1d346c'></a>

**AbbVie Inc. and Subsidiaries**
**Notes to Consolidated Financial Statements**

<a id='fbc0aa31-4f53-4a0b-9c51-9c9f33da4bee'></a>

# Note 1 Background
---
## Background
The principal business of AbbVie Inc. (AbbVie or the company) is the discovery, development, manufacturing and sale of a broad line of therapies that address some of the world's most complex and serious diseases. AbbVie's products are generally sold worldwide directly to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies and independent retailers from AbbVie-owned distribution centers and public warehouses. Certain products (including aesthetic products and devices) are also sold directly to physicians and other licensed healthcare providers. In the United States, AbbVie distributes pharmaceutical products principally through independent wholesale distributors, with some sales directly to retailers, pharmacies, patients or other customers. Outside the United States, AbbVie sells products primarily to wholesalers or through distributors, and depending on the market works through largely centralized national payers systems to agree on reimbursement terms.

<a id='df8147fc-f561-41ff-9415-d66e3603044a'></a>

AbbVie was incorporated in Delaware on April 10, 2012. On January 1, 2013, AbbVie became an independent, publicly-traded company as a result of the distribution by Abbott Laboratories (Abbott) of 100% of the outstanding common stock of AbbVie to Abbott's shareholders.

<a id='e91fa106-cf5d-4e06-99a0-851271d2d9f9'></a>

AbbVie completed its previously announced acquisitions of ImmunoGen, Inc. (ImmunoGen) on February 12, 2024 and Cerevel Therapeutics Holdings, Inc. (Cerevel Therapeutics) on August 1, 2024. See Note 5 and Note 10 for additional information regarding these acquisitions.

<a id='110b15ff-fa37-40ce-a17f-00bc2ae4369a'></a>

Note 2 Summary of Significant Accounting Policies

<a id='4804b321-7c0c-4d8d-aaa9-b1726daf347e'></a>

### Use of Estimates
The consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) and necessarily include amounts based on estimates and assumptions by management. Actual results could differ from those amounts. Significant estimates include amounts for rebates, pension and other post-employment benefits, income taxes, litigation, valuation of goodwill and intangible assets and contingent consideration liabilities.

<a id='083a84f0-5ada-44b8-bb0f-39e3e83f5029'></a>

## Basis of Consolidation
The consolidated financial statements include the accounts of AbbVie and all of its subsidiaries in which a controlling interest is maintained. Controlling interest is determined by majority ownership interest and the absence of substantive third-party participating rights or, in the case of variable interest entities, where AbbVie is determined to be the primary beneficiary. Investments in companies over which AbbVie has a significant influence but not a controlling interest are accounted for using the equity method with AbbVie's share of earnings or losses reported in other expense, net in the consolidated statements of earnings. Intercompany balances and transactions are eliminated. Certain reclassifications have been made to conform the prior period consolidated financial statements to the current period presentation.

<a id='7667a964-c977-4305-8db9-5681f440daa7'></a>

**Revenue Recognition**

AbbVie recognizes revenue when control of promised goods or services is transferred to the company's customers, in an amount that reflects the consideration AbbVie expects to be entitled to in exchange for those goods or services. Sales, value add and other taxes collected concurrent with revenue-producing activities are excluded from revenue. AbbVie generates revenue primarily from product sales. For the majority of sales, the company transfers control, invoices the customer and recognizes revenue upon shipment to the customer. The company recognizes shipping and handling

<a id='81767364-8c42-4453-b90f-52fa702ebea0'></a>

60

<a id='ccaa5509-0b8e-4110-a234-bb23bd9e0df1'></a>

abbvie

<a id='47a38033-d8bd-4557-88b0-c8f1c1f35f13'></a>

2024 Form 10-K